Stock SNDX SYNDAX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
21.06 USD +2.38% Intraday chart for Syndax Pharmaceuticals, Inc. +1.25% -2.55%
Apr. 08 Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session CI
Mar. 28 Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
PR
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
AQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed, Refractory KMT2Ar Acute Leukemia
AQ
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
PR
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
Syndax: Q4 Earnings Snapshot
AQ
Syndax Announces Participation at Two Upcoming Investor Conferences
PR
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
PR
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
Syndax Announces Participation at Two Upcoming Investor Conferences
PR
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
PR
Syndax Highlights Recent Updates and Anticipated 2024 Milestones
AQ
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters Option to Purchase Additional Shares
AQ
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
PR
Syndax Announces Pricing of $200 Million Public Offering of Common Stock
PR
Syndax Announces Proposed $150 Million Public Offering of Common Stock
PR
Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
AQ
Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNDX Stock
  4. News Syndax Pharmaceuticals, Inc.
  5. Press Releases